SINTX Regains Nasdaq Compliance, Supporting Growth Initiatives
I'm LongbridgeAI, I can summarize articles.SINTX Technologies regained compliance with Nasdaq's minimum stockholders' equity requirement, resolving a previous deficiency. This milestone supports the company's growth initiatives, including the commercialization of silicon nitride medical products and expansion of its distribution network. Despite this positive regulatory update, analyst sentiment remains mixed; while one rating suggests a 'Buy,' TipRanks’ AI Analyst rates SINT as 'Neutral' due to weak financial performance, significant losses, and cash burn concerns.
The latest update is out from Sintx Technologies ( (SINT) ).
On August 12, 2026, SINTX Technologies received notice from Nasdaq’s Listing Qualifications Staff that it had regained compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement of $2.5 million under Listing Rule 5550(b)(1). The decision followed SINTX’s June 30, 2026 Quarterly Report, which showed stockholders’ equity of approximately $4.83 million, leading Nasdaq to close the previously disclosed deficiency matter.
Management characterized the restored compliance as an important milestone in efforts to strengthen the company and maintain its listing as it pursues commercialization of its silicon nitride technologies. The resolution of the listing issue supports SINTX’s ongoing plans to advance its silicon nitride‑based medical products, expand its distribution network, and pursue strategic partnerships aimed at supporting future growth and reinforcing its competitive position in advanced medical ceramics.
The most recent analyst rating on (SINT) stock is a Buy
with a $10.00 price target.
To see the full list of analyst forecasts on Sintx Technologies stock,
see the SINT Stock Forecast page.
Spark’s Take on SINT Stock
According to Spark, TipRanks’ AI Analyst, SINT is a Neutral.
The score is held down primarily by weak financial performance (negative gross profit, extremely large losses versus revenue, and substantial ongoing cash burn) and a strained equity position. Technicals are neutral-to-bearish on trend (below longer-term moving averages), while valuation offers limited support due to losses and no dividend. Corporate events are a modest offset due to commercialization progress and new funding, but are tempered by Nasdaq noncompliance and dilution-related risk.
To see Spark’s full report on SINT stock,
click here.
More about Sintx Technologies
SINTX Technologies, Inc. is an advanced ceramics company based in Salt Lake City, Utah, that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high‑value applications. Its business spans proprietary biomaterials and medical device technologies, contract manufacturing, and other advanced ceramics opportunities, and its portfolio includes the FDA‑cleared SINAPTIC Foot & Ankle Implant System for reconstructive surgery.
The company leverages peer‑reviewed research, a patent portfolio, U.S.‑based manufacturing capabilities, and strategic industry relationships to support its market presence in silicon nitride‑based medical products. It focuses on advancing commercialization, expanding its distribution network, and building strategic partnerships to underpin future revenue growth and broaden its reach in the medical technology sector.
Average Trading Volume: 110,948
Technical Sentiment Signal: Sell
Current Market Cap: $11.25M
For a thorough assessment of SINT stock, go to TipRanks’ Stock Analysis page.